---
mi_id: MIPR-node_4f501c1
type: press_release
canonical_url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/volume-grew-3-20-revenue-fell-13-77-price-per-immunoassay-test-fell-16-44/"
md_url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/volume-grew-3-20-revenue-fell-13-77-price-per-immunoassay-test-fell-16-44.md"

schema:
  "@type": NewsArticle
  "@id": MIPR-node_4f501c1
  url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/volume-grew-3-20-revenue-fell-13-77-price-per-immunoassay-test-fell-16-44/"
  title: "The Volume Grew 3.20 Per Cent and the Revenue Fell 13.77 — the Difference Is a 16.44 Per Cent Price Cut per Test, and 38 Per Cent of the Menu Was Priced in a Single Award Notice"
  description: "Pheonix Research sizes the global immunoassay market at USD 26,400m in 2025 rising to USD 38,710m by 2033 at 4.90%. One vendor's disclosed reagent revenue and volume growth measure a 16.44 per cent fall in the price of a test in China and 6.00 per cent overseas."
  datePublished: "2026-11-15T13:15:59+00:00"
  dateModified: "2026-11-15T13:16:32+00:00"
  keywords:
    - immunoassay market
    - chemiluminescence market
    - CLIA market size
    - immunoassay price per test
    - China volume-based procurement diagnostics
    - tumour marker testing
    - thyroid function testing
    - immunoassay forecast 2033
  isPartOf:
    - id: MISG-node_7e576db
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/diagnostics/"
      name: Diagnostics
    - id: MIIN-node_50b4dbf
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/"
      name: Healthcare
    - id: MIWS-root
      type: WebSite
      url: "https://www.pheonixresearch.com/"
      name: Pheonix Research

acf:
  phoenix_meta_title: "Immunoassay: Volume +3.20%, Revenue −13.77%, Price per Test −16.44%"
  phoenix_meta_description: "Pheonix Research sizes the global immunoassay market at USD 26,400m in 2025 rising to USD 38,710m by 2033 at 4.90%. One vendor's disclosed reagent revenue and volume growth measure a 16.44 per cent fall in the price of a test in China and 6.00 per cent overseas."

global_schema:
  organization:
    "@id": MIWS-root#organization
    "@type": Organization
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  website:
    "@id": MIWS-root
    "@type": WebSite
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  api:
    "@id": MIWS-root#api
    "@type": WebAPI
    url: "https://www.pheonixresearch.com/"

graph:
  node_id: MIPR-node_4f501c1
  graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MIPR-node_4f501c1"
  graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph"
  graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions"
  graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta"
  graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle"

discovery:
  discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json"
  llms_txt: "https://www.pheonixresearch.com/llms.txt"
  sitemap: "https://www.pheonixresearch.com/sitemap.xml"
---
# The Volume Grew 3.20 Per Cent and the Revenue Fell 13.77 — the Difference Is a 16.44 Per Cent Price Cut per Test, and 38 Per Cent of the Menu Was Priced in a Single Award Notice

Pheonix Research has published *Global Immunoassay Market Report, Size, Share and Forecast 2026-2033: The Volume Grew and the Revenue Didn’t*, which sizes the discipline at **USD 26,400 million in 2025**, reaching **USD 38,710 million by 2033** at a compound annual rate of **4.90 per cent** — **1.47 times** the base year and **USD 12,310 million** of incremental annual revenue across eight years. The full report is available at [pheonixresearch.com](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-immunoassay-market/).

The finding is that immunoassay is the largest discipline in in vitro diagnostics and, on this construction, one of the slowest-growing: its share of the USD 104.9 billion diagnostics base falls from **25.17 per cent to 23.48 per cent** by 2033, a loss of 1.69 points. That is not a demand forecast. Roche delivered **31 billion diagnostic tests** to customers during 2025, and the installed base of analysers was larger at the end of the year than at the start in every region. It is a price forecast, and the base year contains the measurement.

In 2025 the two densest reagent categories in Chinese chemiluminescence — tumour markers and thyroid function — were priced by a provincial procurement alliance rather than by a vendor, at an average **50 per cent below the published ceiling price**. One company then disclosed both halves of what that did. **Snibe’s domestic reagent revenue fell 13.77 per cent while its domestic reagent volume rose 3.20 per cent**, a realised price per test of **minus 16.44 per cent**. Overseas, in geographies where no alliance sets a price, reagent revenue rose 34.96 per cent on volume growth of 43.57 per cent — **minus 6.00 per cent**. Two continents, one disclosure, two deflation rates, and in neither of them is demand the problem.

 | Indicator |  | 2025 |  | 2033 |  | Change |

 | Market value (USD million) |  | 26,400.0 |  | 38,710.0 |  | +12,310.0 |

 | CAGR, 2025–2033 |  | 4.90% (1.47x) |

 | Share of global in vitro diagnostics value |  | 25.17% |  | 23.48% |  | −1.69 pp |

 | Chemiluminescence (CLIA, CMIA, ECLIA) |  | 16,368 (62.0%) |  | 25,020 (64.6%) |  | 5.45% CAGR |

 | ELISA and microplate |  | 3,696 (14.0%) |  | 4,640 (12.0%) |  | 2.88% CAGR |

 | Tumour markers and thyroid function (both priced in 2024) |  | 10,032 (38.0%) |  | 13,200 (34.1%) |  | −3.9 pp |

 | Neurodegeneration and other emerging analytes |  | 528 (2.0%) |  | 1,520 (3.9%) |  | 14.13% CAGR |

 | China |  | 5,016 (19.0%) |  | 6,968 (18.0%) |  | 4.19% CAGR |

 | Attributed to nine disclosed corporate pools |  | 17,583 (66.6%) |  | Stated residual 8,817 (33.4%) |

 | Change in realised price per domestic chemiluminescence test, largest listed Chinese vendor |  | −16.44% |  | Change per overseas reagent sale, same vendor: −6.00% |

## One company disclosed the price of a test, and disclosed it twice

Almost no vendor in this market publishes reagent revenue and reagent volume separately. Snibe does, and the pair is what turns a qualitative story about procurement into a number.

In China the two lines diverge by **16.97 percentage points** of growth — revenue at minus 13.77, volume at plus 3.20 — which resolves to a realised price of minus 16.44 per cent per test. Overseas the same two lines diverge again, in the same direction, at a fraction of the magnitude: revenue plus 34.96, volume plus 43.57, price minus 6.00 per cent. That is a **10.44-point spread in the rate at which the same company’s price was eroded**, in the same year, selling the same reagents off the same platforms.

The overseas number is not a procurement effect. There is no alliance setting prices in Latin America or Southeast Asia. It is either mix or competition, and the report does not claim to know which. What it does claim is that a model treating the Chinese reset as the only deflation in the category will overstate the recovery — because price per test was falling everywhere, and being destroyed in one place.

What the Chinese reset bought and what it cost are both visible in the same filing. Snibe runs a **250-item chemiluminescence menu**, 207 of them with European market access, on an installed base of **4,761 MAGLUMI X8 units**, serving **1,930 Chinese tertiary hospitals — 46.95 per cent coverage and 63.38 per cent of the top-tier 3A hospitals**. In 2025 it installed 1,462 analysers in China, 79.14 per cent of them large-frame, and 3,357 overseas, 75.34 per cent mid-to-large. A vendor with that menu density and that institutional reach still lost 13.77 per cent of its domestic reagent revenue, and lost it on price rather than on volume. Net profit was RMB 1,620.3 million on revenue of RMB 4,576.8 million, a 35.40 per cent margin held while the domestic price was cut by a sixth.

## Roche’s core laboratory is 70 per cent immunoassay, and that is solved rather than assumed

Roche reports core laboratory as a single number and then discloses the growth of two lines inside it. For 2025 the number was **flat at CHF 7,600 million**. Immuno-diagnostics fell **3 per cent**. Clinical chemistry rose **7 per cent**.

There is only one weight on those two lines that makes them sum to zero, and it is **70 per cent immunoassay to 30 per cent chemistry**. The report takes that weight from the disclosed growth rates rather than assuming a share and burying it, and the consequence is not a small one: Roche’s immunoassay line is worth **CHF 5,320 million, or USD 6,118 million** at 1.15 to the franc, the largest single attributed pool in a USD 26,400 million market at **23.17 per cent**. A three per cent decline in a line that is seven-tenths of a business is enough to hold the entire business flat while the discipline next to it grew seven.

The geography says the same thing from a different direction. Roche’s diagnostics sales in China fell **24 per cent** for the year and took Asia-Pacific down **12 per cent**, while every other region grew at a mid-single-to-low-double-digit rate. Abbott’s Core Laboratory revenue was **USD 5,360 million, up 2.29 per cent** from USD 5,240 million, and its fourth quarter grew 5.3 per cent reported and 3.6 per cent organically — a result the company hedged by naming “challenging market conditions in China, including the impact of volume-based procurement programs.” DiaSorin’s ex-COVID immunodiagnostics revenue was **EUR 821 million, up 7 per cent at constant rates and up 8 per cent excluding China**, and the company attributed the Chinese contraction to procurement directly. QuidelOrtho’s Labs revenue was **USD 1,505.7 million, up 5.7 per cent in constant currency**, almost all of it Vitros sold overwhelmingly into the United States, where no alliance sets a reagent price — the cleanest control group in the dataset, and it grew roughly eight points faster than Roche’s immunoassay line.

A fourth disclosure sets the margin against the pricing. Danaher’s diagnostics segment earned **USD 2,650 million of operating profit on USD 9,941 million of revenue, 26.66 per cent**. DiaSorin earned an adjusted EBITDA of EUR 394 million on EUR 1,195 million, **32.97 per cent**. Siemens Healthineers Diagnostics earned an adjusted EBIT of EUR 333 million on EUR 4,347 million, **7.66 per cent**, up from 5.3 per cent as it took cost out of a broad estate. The four measures are not the same measure — adjusted EBITDA, adjusted EBIT and segment operating profit are three different things — so the table they form is directional rather than a ranking. What it shows is a spread from under eight per cent to over thirty inside a single product category, and the explanation is not assay quality. It is menu density per placement, which is the variable a procurement alliance prices.

## The platform generation is finished; the analyte generation is where the growth is

Chemiluminescence, whether acridinium-ester direct, enzyme-amplified or electrochemiluminescent, has been the reference principle for four decades, and nothing in 2025 displaced it. It takes **62.0 per cent of the market in 2025 and 64.6 per cent by 2033**, growing 5.45 per cent a year. ELISA and microplate testing falls from **14.0 to 12.0 per cent** at 2.88 per cent, not because it stops working but because a plate carries no annuity, no random access and more labour per result, so every additional sample makes a closed system relatively cheaper.

What changed in 2025 is what goes on the analyser. Roche’s **Elecsys Phospho-Tau (217P) Plasma** was cleared as **510(k) K261686**, a Class II device under 21 CFR 866.5840, running as a fully automated electrochemiluminescence immunoassay on cobas e analysers for patients aged 55 and over with signs of cognitive decline. It reports three bands rather than a number — positive above 0.378 pg/mL, intermediate between 0.223 and 0.378, negative at or below 0.223 — and it is the first single-biomarker blood test cleared to aid identification of amyloid pathology. That converts a PET scan into a reagent on an installed base that already exists. Danaher’s Beckman Coulter expanded its DxI 9000 menu with disclosed progress in neurodegenerative assays. bioMérieux’s VIDAS TBI runs GFAP and UCH-L1 for mild traumatic brain injury alongside NEPHROCHECK and a fully automated TB IGRA, on a platform of more than eighty tests running up to 72 results an hour with six KUBE modules. Sysmex launched an Alzheimer’s reagent in Japan in 2022 and is rolling it into Europe and the United States on its HISCL line.

None of those analytes sits inside a volume-based procurement category, which is the point of them. Neurodegeneration and other emerging analytes are the smallest row in the application table and the fastest-growing: **USD 528 million to USD 1,520 million, 2.0 to 3.9 per cent of the market, at 14.13 per cent a year**. The cutoff table is as much of the commercial object as the antibody is — it is what makes the test billable and what makes it defensible — and it is why a new analyte takes years to reach a menu while a new analyser takes months.

## Thirty-eight per cent of the menu was priced by a committee, and it loses 3.9 points

The 2023 Anhui-led round covered sex hormones and infectious disease serology and averaged a **51 per cent reduction**. The 2024 round published on 30 December 2024 extended the mechanism to **sixteen tumour marker items and nine thyroid function items** — twenty-five items, the two largest chemiluminescence categories in the country — awarded at an average **50 per cent below the published ceiling price** in Group A, with **every winning bidder receiving 100 per cent of its intended volume**. The ceilings themselves had been set at 34 and 45 per cent of the Beijing public hospital test price. A vendor that declined to bid left the province; a vendor that bid accepted the ceiling; and volume, having been fully allocated to the winners, could not be used to recover the difference.

Those two categories are **38.0 per cent of the 2025 market** and fall to **34.1 per cent by 2033**. Cardiac markers overtake thyroid function to become the second-largest application at **USD 5,850 million**, growing 5.91 per cent, because troponin and natriuretic peptide testing is driven by guideline-defined care pathways and by emergency departments that cannot batch a result. Cardiac markers are also the obvious next candidate for the same treatment: they are 14.0 per cent of the market, they run on the same analysers as the categories already reset, and if they price the way tumour markers did the terminal market is **USD 37,727 million at 4.56 per cent**. The report regards that as more likely to happen inside the window than not.

## A third of this market files no accounts, and that is not the same as an unconcentrated market

Nine disclosed corporate pools account for **USD 17,583 million of the USD 26,400 million base, or 66.6 per cent**. The remaining **USD 8,817 million, 33.4 per cent**, is stated as a block rather than distributed: Chinese domestic vendors below the two named, ELISA and open-platform suppliers, Indian, Korean, Japanese and Brazilian specialists, and hospital in-house microplate work. An ELISA reagent sold by a distributor into a research hospital is a real transaction and there is no filing that records it.

That residual is an attribution gap, not an absence of competition, and the distinction is the whole argument. The tail is unlisted, not vacant — which is precisely why a procurement authority can fill twenty-five categories with qualified bidders and defend the ceiling it sets. Open-platform reagents also price against nothing but each other, so their unit prices are visible in a way a chemiluminescence cartridge price is not, and that visibility is the reference a closed-system vendor is argued down toward. Set the same residual measure against the cluster’s haematology report, where **87.28 per cent** of value attributes to named vendors, and the contrast is the finding: a six-part differential cannot be assembled from third-party reagents, so haematology has almost nothing unlisted; and it was still repriced, in a Chinese provincial tender that cut six coagulation items by an average 40.16 per cent. A market can be fully disclosed and still be administered, and a market can be a third unlisted and still be priceable. What decides which is whether a buyer has an alternative to point at.

## The risk no price model captures, and the band it produces

Mindray’s in vitro diagnostics revenue fell **9.41 per cent to RMB 12,241 million** against a **22.97 per cent** domestic decline, and the company named four causes in a single sentence: DRG/DIP payment reform, reagent volume-based procurement, mutual recognition of test results across institutions, and medical service price governance. **Two of those four act on volume, not on price.** Panel unbundling removes the bundled order that fills an immunoassay menu, and mutual recognition means a result obtained in one hospital is accepted in another instead of being repeated — and a repeated test is a reagent sale. This is the least modelled exposure in the category, it acts on the numerator of price times volume, and no participant discloses placement attrition in a form that would let a reader measure how durable the annuity actually is.

Three scenario paths bound the market, and none of them assumes demand falls. China growing at 1.5 per cent rather than 4.2 takes the terminal value to **USD 37,392 million at 4.45 per cent**. Cardiac markers pricing the way tumour markers did takes it to **USD 37,727 million at 4.56 per cent**. Neurodegeneration growing at 18 per cent rather than 14, with inflammation and sepsis at 8.5 rather than 7.2, takes it to **USD 39,474 million at 5.16 per cent**. The base case is not a China recovery story; it is a story about the rest of the world growing while China transacts.

Currency is a fifth variable that is not a risk to demand and is routinely mistaken for one. Roche’s diagnostics division grew 2 per cent at constant exchange rates and fell 3 per cent in Swiss francs — a five-point gap created entirely by translation. DiaSorin absorbed a EUR 34 million currency impact on EUR 1,195 million of revenue and still grew 1 per cent at current rates against 4 per cent at constant rates.

## What is inside the perimeter, and why the level is where it is

**Inside:** reagents, instruments, calibration, service and software sold for the detection and quantification of antigens and antibodies in central and hospital laboratories — chemiluminescence in all three chemistries, microplate ELISA, immunoturbidimetric and latex-enhanced assays run on chemistry analysers, fluorescent enzyme-linked formats, and multiplex bead and flow arrays. Both the reagent annuity and the instrument placement are counted, because in a closed system they are one commercial transaction.

**Outside:** lateral-flow and rapid point-of-care immunoassay, which belongs to the point-of-care discipline and is sized separately in the cluster; molecular diagnostics; blood banking immunohematology, which is a donor and transfusion market with its own regulator; donor screening; veterinary and food-safety immunoassay, including the industrial VIDAS applications that share bioMérieux’s instrument but not its buyer; self-testing; and laboratory-developed tests sold as a service rather than a product. The perimeter matters because two honest analysts can arrive at USD 26 billion or USD 42 billion for “immunoassay” and both be right — the larger number includes lateral flow and point-of-care, which is the fastest-growing part of antigen-antibody testing and is not in this report.

On that perimeter the level is **25.17 per cent of the USD 104.9 billion diagnostics base** used across the cluster. The reagents themselves sit inside the **USD 78,400 million** consumable layer at **USD 21,638 million, or 27.60 per cent**, growing **4.55 per cent** against a 5.31 per cent layer average — because the reagent is the only part of a closed chemiluminescence system that a provincial alliance can specify.

The method is a deliberate 70/30 split between secondary and primary evidence. The secondary layer is the disclosed record: annual reports, results releases and capital-markets presentations from Roche, Abbott, Danaher, Siemens Healthineers, QuidelOrtho, bioMérieux, DiaSorin, Snibe, Mindray and Sysmex; provincial procurement award notices from China; and FDA clearance records. It was read in full and reconciled line by line, and no third-party market research estimate was used at any point. The primary layer is 38 depth interviews conducted between the first quarter of 2025 and the third quarter of 2026 across twelve markets with laboratory directors and clinical biochemists, immunoassay commercial and market-access leaders, procurement and group purchasing executives and distributor principals; 24 open-ended interviews with laboratory managers who had run a reagent tender in the preceding eighteen months; a structured survey of 187 laboratory operations and procurement decision-makers fielded in the second quarter of 2026; and observation at AACC/ADLM 2026, Medica 2025, ESCMID Global 2026 and the J.P. Morgan Healthcare Conference 2026. The primary layer explains mechanism — how a tender is sequenced, what a laboratory does when a reagent price is reset, why a menu is rationalised after a placement — and is never used to carry a figure. Every growth rate in the report is a participant’s own reported constant-currency or organic figure, or is implied by the endpoints in the document; every price-per-test figure is a revenue growth rate divided by a volume growth rate from the same disclosure, with the arithmetic shown. Currency translation uses 2025 average rates throughout: EUR 1.00 = USD 1.13, CHF 1.00 = USD 1.15, JPY 148 = USD 1.00, CNY 7.20 = USD 1.00.

## Related research in this cluster

[Global In Vitro Diagnostics Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-in-vitro-diagnostics-ivd-market/) — the head report, USD 104.9 billion in 2025 to USD 164.9 billion in 2033 at 5.82 per cent, and the base this discipline reconciles to. [Global Clinical Chemistry and Urinalysis Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-clinical-chemistry-and-urinalysis-market/) — the other half of the routine core, USD 16,800 million at 3.71 per cent, which reads the chemistry side of Roche’s flat core laboratory. [Global Haematology and Coagulation Diagnostics Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-haematology-and-coagulation-diagnostics-market/) — USD 7,620 million at 4.25 per cent, and the contrast in attributability: 87.28 per cent of its value names a vendor, against 66.6 per cent here. [Global Microbiology Diagnostics Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-microbiology-diagnostics-market/) — USD 8,830 million at 5.14 per cent, the only discipline in the cluster where realised revenue per test rises. [Global IVD Reagents and Consumables Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-ivd-reagents-and-consumables-market/) — the USD 78.4 billion consumable layer this discipline’s reagents sit inside. [Global Infectious Disease Diagnostics Market, 2026–2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-infectious-disease-diagnostics-market/) — the application layer where serology and immunoassay pathogen detection is USD 5,900 million, growing 3.21 per cent.

## Companion analysis

Three articles read this report’s evidence from different ends. [China’s Price Cut Is Worth Half a Point of the IVD Forecast, Not Four](https://www.pheonixresearch.com/healthcare/diagnostics/article/chinas-price-cut-is-worth-half-a-point-of-the-ivd-forecast-not-four/) takes a base-year reset apart and shows how much of it dilutes as a compound annual rate is computed across eight years — the arithmetic behind this report’s 4.90 per cent setting against a diagnostics base growing at 5.82. [Two Diagnostics Businesses, the Same Operating Profit, a Quarter of the Revenue](https://www.pheonixresearch.com/healthcare/diagnostics/article/two-diagnostics-businesses-the-same-operating-profit-a-quarter-of-the-revenue/) is the margin consequence: the same operating profit earned on a quarter of the revenue, which is what menu density per placement buys. [Fifteen Per Cent a Year: How the Price Schedule Decides Diagnostic Growth](https://www.pheonixresearch.com/healthcare/diagnostics/article/fifteen-per-cent-a-year-how-the-price-schedule-decides-diagnostic-growth/) is the reimbursement side of the same mechanism, where an administered rate rather than a procurement award sets what a laboratory can pay.

## About this report

*Global Immunoassay Market Report, Size, Share and Forecast 2026-2033: The Volume Grew and the Revenue Didn’t* is USD 26,400 million of 2025 market value built from nine attributed corporate pools and a stated residual, with three scenario paths, a full technology, application and regional segmentation, a derivation of one vendor’s 70/30 line split from its own disclosed growth rates, and a value-chain and margin analysis of where rent accrues in a discipline whose instrument is a toll gate and whose reagent is the annuity. It is one of six discipline and layer reports that reconcile to a single USD 104.9 billion in vitro diagnostics base.

## About Pheonix Research

Pheonix Research produces market intelligence for decisions that turn on price, volume and structure rather than on narrative. Its method is to build a market from disclosed pools upward, state the residual rather than absorb it, and put a number on the mechanism that sets the price — here, a provincial procurement award and a reagent price per test that one company happened to publish in two geographies.
